There was a discussion yesterday about the attention CYDY will receiver after the licensing agreement is made and how that will increase the SP/market cap. The partner, who NP described as a mid-level BP, no doubt has many more investors and is worth billion of dollars. When the deal is PRed by that company, many will flock to CYDY to read up on Leronlimab. I can’t imagine that we won’t get an increase in volume and SP because of that.

But like you, I am worried that the time between BLA submission and revenues may require more dilution depending on how much cash we get upfront and whether other indications (NASH, mTNBC, etc) bring in a licensing deal and upfront cash as well.